Mangala started her career in research at the National University of Singapore, before completing her Ph.D. at Carnegie Mellon University (USA). She is currently an Asst. Professor (Group Leader) at the Dept. of Tumor Immunology, at the Radboud University Medical Center in Nijmegen, the Netherlands. Her work focuses on agents for in vivo imaging. Mangala's early work helped established the field of 19F MRI for quantitative in vivo cell tracking, including the first paper on the topic. More recently, her group works on customisable nanoparticles for imaging and advanced personalised medicine applications. Some of these nanoparticles are produced at GMP-grade for a clinical cell tracking study using multimodal imaging, in melanoma patients. Her group works with fluorescence, MRI, PET, SPECT, ultrasound and photoacoustic imaging in several disease models, particularly cancer and cardiovascular disease. A spin-off to bring the nanoparticles to the patient on a larger scale is being set-up. This multidisciplinary work is, or has been, supported by prestigious grants such as an NWO Veni, ERC Starting Grant, ERA-NET CVD grant, and others. Mangala is also active within the Young Academy of Europe, and is currently elected to the Board as Vice Chair, and served as Category Chair for the European Molecular Imaging Meetings. She is also an Associate Editor for the journal European Reviews, and currently a Guest Editor for an Special Issue on 19F MRI in the journal MAGMA.
Website link: https://www.multiscaleimaging.com/
In vivo imaging, cell tracking, 19F MRI, MRI, SPECT, ultrasound, photoacoustics, optoacoustics, nanoparticles, targeting, PLGA particles, perfluorocarbons